Mondelez International Inc. (MDLZ) Q3 2026: Gaps +3.6% at Open — Post-Earnings Analysis
QuoteReporter
•5 min read
EARNINGS DAY PRICE ACTION — MDLZ
Gapped Up +3.61%Prev close $62.53 → Open $64.79
# Mondelēz International (MDLZ) Q4 2025 Financial Results Summary
CHICAGO, Ill. – On February 3, 2026, Mondelēz International, Inc. (Nasdaq: MDLZ) announced its fourth quarter and full year 2025 financial results, displaying significant changes in revenues, margins, and earnings.
## Key Highlights
- **FY 2025 Performance:**
- **Net Revenues:** Increased by **5.8%** year-over-year to **$38.54 billion**.
- **Organic Net Revenue Growth:** **4.3%** driven by higher net pricing, partially offset by a **3.7%** decline in volume/mix.
- **Diluted EPS:** Declined by **44.7%** compared to prior year, now at **$1.89**.
- **Adjusted EPS:** Down **14.6%** on a constant currency basis to **$2.92**.
- **Cash Provided by Operating Activities:** Totaled **$4.5 billion**.
- **Free Cash Flow:** Reported at **$3.2 billion**.
- **Return of Capital to Shareholders:** **$4.9 billion** through dividends and share repurchases.
- **Q4 2025 Performance:**
- **Net Revenues:** Rose **9.3%** year-over-year to **$10.50 billion**.
- **Organic Net Revenue Growth:** **5.1%** comprising **8.5%** pricing and a **4.8%** volume/mix decline.
- **Gross Profit:** Fell by **20.3%** to **$2.96 billion**, with a gross profit margin of **28.2%**, down by **10.4 percentage points**.
- **Operating Income:** Decreased **40.9%** to **$952 million**, equating to an operating income margin of **9.1%**, down **7.7 percentage points**.
- **Net Earnings:** Dropped **61.9%** to **$665 million**.
- **Diluted EPS:** Declined **60.8%** to **$0.51**.
- **Adjusted EPS:** Increased by **4.6%** on a constant currency basis to **$0.72**.
## Revenue Breakdown by Regions for Q4 2025
- **Latin America:**
- Net Revenues: **$1,264 million** (+7.9% vs. Q4 2024)
- Organic Growth: **4.4%** (Pricing +8.5%, Volume/Mix -4.1%)
- **Asia, Middle East & Africa:**
- Net Revenues: **$2,078 million** (+8.9%)
- Organic Growth: **7.5%** (Pricing +9.3%, Volume/Mix -1.8%)
- **Europe:**
- Net Revenues: **$4,391 million** (+17.3%)
- Organic Growth: **8.3%** (Pricing +15.7%, Volume/Mix -7.4%)
- **North America:**
- Net Revenues: **$2,763 million** (-0.6%)
- Organic Growth: **-0.5%** (Pricing +3.2%, Volume/Mix -3.7%)
## Financial Metrics Overview
- **Gross Profit Margin**: Decreased from **38.6%** in Q4 2024 to **28.2%** due to increased commodity costs and changes in product mix.
- **Operating Income Margin**: Fell from **16.8%** in Q4 2024 to **9.1%**. Adjusted Operating Income margin rose from **10.0%** to **11.9%**.
- **Net Earnings for FY 2025:** Dropped **46.8%** to **$2.45 billion**.
## Dividend and Share Repurchase Information
- Mondelēz announced a **return of $4.9 billion** to shareholders, which included both cash dividends and share repurchases.
## FY 2026 Outlook
- **Organic Net Revenue Growth:** Expected to range from flat to **2%**.
- **Adjusted EPS Growth:** Forecasted to be flat to **5%** on a constant currency basis.
- **Free Cash Flow**: Projected around **$3 billion**.
The company aims to focus on pricing strategy, structural cost savings, brand investments, and disciplined capital allocation as it navigates through ongoing challenges such as commodity price inflation and macroeconomic volatility.
Mondelēz International remains committed to driving sustainable, profitable growth as it leverages its scale and strong brand portfolio in the upcoming year.
Here are the extracted tables from the press release:
### Condensed Consolidated Statements of Earnings
(in millions of U.S. dollars and shares, except per share data)
---
### Condensed Consolidated Balance Sheets
(in millions of U.S. dollars)
Quarterly Earnings — Revenue vs. Estimate
Quarter Label
Quarter End
Rev Actual ($M)
Rev Est ($M)
Rev Var ($M)
EPS Actual
EPS Est
EPS Beat
Q3 2026
2026-10
9,970
9,980
-10
0.78
0.71
+0.07
Q2 2026
2026-07
9,360
9,210
+150
0.73
0.68
+0.05
Q1 2026
2026-03-31
10,080
9,750
+330
0.67
0.61
+0.06
Q4 2025
2025-12-31
10,500
10,320
+180
0.72
0.70
+0.02
Q3 2025
2025-09-30
9,740
9,760
-20
0.73
0.74
-0.01
Revenue vs. Estimate — 5 Quarters
EPS vs. Estimate — 5 Quarters
Technical Analysis — 90-Day Price Chart
Mondelez International Inc. (MDLZ) trades at $64.78, comfortably above its key moving averages—SMA20 ($62.25) and SMA50 ($61.50)—confirming a bullish near-term trend with no imminent bearish crossovers. The SMA200, though not specified, likely sits lower, reinforcing the upward bias. The RSI(14) at 60.8 suggests neutral momentum, neither overbought nor oversold, leaving room for further upside. Recent volume of 5.41M shares lags behind the 20-day average of 7.22M, indicating muted participation in the current rally. MDLZ hovers near its 52-week high ($66.07), just 2% below, signaling strong resistance ahead, while the 52-week low ($57.27) provides a solid floor. A breakout above $66.07 could accelerate gains, whereas failure may see a retest of SMA20 support. The setup favors cautious optimism, pending confirmation of higher volume on upward moves.
Disclaimer: The content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments carry risk and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting.
EARNINGS DAY PRICE ACTION — SBUXCalm Open (+0.19%)Prev close $105.51 → Open $105.71 — then slid 3.19% intraday
Quarterly Earnings — Revenue vs. Estimate
Quarter Label
Quarter End
Rev Actual ($M)
Rev Est ($M)
Rev Var ($M)
EPS Actual…
Gilead Sciences (GILD) Q3 2026: Revenue Growth Amid Mixed Earnings — Cautiously Optimistic: Gaps +2.6% at Open — Post-Earnings Analysis
EARNINGS DAY PRICE ACTION — GILDGapped Up +2.65%Prev close $165.61 → Open $170.00 — then rallied 1.39% intraday
Gilead Sciences, Inc. (Nasdaq: GILD) reported its third-quarter 2026 financial results, revealing a total product sales increase of $1.0 billion or +13% year-…
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026: Strong Revenue Growth and Record Sales — Positive Outlook Regeneron Pharmaceuticals, Inc. (REGN) reported a robust performance in the third quarter of 2026, with total revenues increasing by $1.4 billion or +36% year-over-year, reaching $5.1 billion...